Company Description
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States.
It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions.
The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.
It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC.
The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020.
ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
| Country | United States |
| Founded | 1998 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 107 |
| CEO | Joseph Michael Burnett |
Contact Details
Address: 120 S. Sierra Avenue, Suite 100 Solana Beach, California 92075 United States | |
| Phone | (949) 900-6833 |
| Website | clearpointneuro.com |
Stock Details
| Ticker Symbol | CLPT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001285550 |
| CUSIP Number | 18507C103 |
| ISIN Number | US18507C1036 |
| Employer ID | 58-2394628 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Joseph Michael Burnett | President, Chief Executive Officer and Director |
| Danilo D'Alessandro | Chief Financial Officer |
| Jeremy Stigall | Chief Business Officer |
| Mazin Sabra | Chief Operating Officer |
| Ellisa Cholapranee | General Counsel and Secretary |
| Jacqueline Keller | Vice President of Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 5, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 12, 2024 | 10-K | Annual Report |
| Mar 12, 2024 | 8-K | Current Report |
| Mar 1, 2024 | 8-K | Current Report |
| Mar 1, 2024 | 424B2 | Prospectus |
| Feb 28, 2024 | 424B5 | Filing |
| Feb 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jan 29, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 8, 2024 | 8-K | Current Report |